Enthesis healing
Disclosed are devices and methods for improving healing of an enthesis. An effective amount of a composition comprising one or more sex steroids and/or sex steroid equivalents is locally administered at the site of a repaired enthesis. The composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes, resulting in improved healing of the enthesis. The improved enthesis healing occurs even where the subject has normal levels of sex hormones.
1 . A method of improving healing of an enthesis of a subject in need thereof, the method comprising:
locally administering to the subject, at a target enthesis site, an effective amount of a composition comprising
(i) an estrogen, wherein the estrogen comprises one or more of estrone, estradiol, estriol, or ester or ether thereof,
(ii) an androgen and/or androgen equivalent, wherein the androgen comprises one or more of testosterone, dihydrotestosterone, androstenedione, or ester or ether thereof, and wherein the androgen equivalent comprises a selective androgen receptor modulator, or
(iii) combination thereof,
to thereby increase levels of at least one sex steroid at the target enthesis site,
wherein the composition is included in a drug-eluting implant,
wherein the drug-eluting implant is placed in a formed cavity in bone tissue at the target enthesis site; and
the composition improving healing of an enthesis in the subject.
2 . The method of claim 1 , wherein the enthesis is a repaired enthesis.
3 . The method of claim 2 , wherein risk of re-tear injury is reduced due to the improved healing of the enthesis.
4 . The method of claim 1 , wherein the enthesis is associated with an Achilles tendon, rotator cuff tendon, distal biceps and triceps tendon, pectoralis major tendon, flexor and extensor tendon, wrist extensor and flexor tendon, hip abductor tendon, proximal hamstring tendon, patella tendon, quadriceps tendon, peroneal tendon, toe flexor and extensor tendon, anterior cruciate ligament, posterior cruciate ligament, knee medial and lateral collateral ligament, anterior talofibular ligament, calcaneofibular ligament, posterior talofibular ligament, anterior inferior tibiofibular ligament, posterior inferior tibiofibular ligament, ankle deltoid and spring ligament, acromioclavicular ligament, coracoclavicular ligament, sternoclavicular ligament, elbow lateral collateral ligament, elbow medial collateral ligament, radial annular ligament, ligament of the wrist, plantar plate, or collateral ligament of a finger, thumb, or toe.
5 . The method of claim 1 , wherein the composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes.
6 . The method of claim 1 , wherein the selective androgen receptor modulator comprises one or more of enobosarm or ligandrol.
7 . The method of claim 1 , wherein the composition further comprises an aromatase inhibitor.
8 . The method of claim 1 , wherein the composition comprises a combination of sex steroids and/or sex steroid equivalents formulated to increase levels of more than one sex steroid in the subject.
9 . The method of claim 1 , wherein the drug-eluting implant is configured to provide extended release of the composition.
10 . The method of claim 1 , wherein:
the estrogen is included at a dose of 0.05 mg to 8 mg; and/or
the androgen and/or androgen equivalent is included at a dose of 2.5 mg to 200 mg.
11 . The method of claim 1 , wherein the composition omits other active compounds for improving healing of the enthesis.
12 . The method of claim 1 , wherein the composition comprises a carrier, and wherein the carrier comprises a solvent, solution, emulsion, suspension, coating, isotonic agent, dispersion media, suspension media, absorption promoting agent, absorption delaying agent, suspending agent, thickening agent, preservative, antimicrobial agent, salt, liposome, polymeric micelle, microsphere, nanoparticles, or combination thereof.
13 . The method of claim 1 , wherein the drug-eluting implant is cylindrically-shaped.
14 . The method of claim 1 , wherein the drug-eluting implant is configured to hold about 0.10 ml to about 0.5 ml of the composition.
15 . The method of claim 1 , wherein the drug-eluting implant includes one or more ports enabling elution of the composition.
16 . A method of improving healing of an enthesis of a subject in need thereof, the method comprising:
locally administering to the subject, at a target enthesis site, an effective amount of a composition comprising
(i) an estrogen, wherein the estrogen comprises estrone, estradiol, estriol, ester thereof, ether thereof, or combination thereof,
(ii) an androgen and/or androgen equivalent, wherein the androgen comprises testosterone, dihydrotestosterone, androstenedione, ester thereof, ether thereof, or combination thereof, and wherein the androgen equivalent comprises a selective androgen receptor modulator, or
(iii) combination thereof,
wherein the composition omits selective estrogen receptor modulators,
to thereby increase levels of at least one sex steroid at the target enthesis site,
wherein the composition is included in a drug-eluting implant,
wherein the drug-eluting implant is placed adjacent to or internal to a ligament or a tendon at the target enthesis site; and
the composition improving healing of an enthesis in the subject.
17 . The method of claim 16 , wherein the enthesis is a repaired enthesis and wherein risk of re-tear injury is reduced due to the improved healing of the enthesis.
18 . The method of claim 16 , wherein the enthesis is associated with an Achilles tendon, rotator cuff tendon, distal biceps and triceps tendon, pectoralis major tendon, flexor and extensor tendon, wrist extensor and flexor tendon, hip abductor tendon, proximal hamstring tendon, patella tendon, quadriceps tendon, peroneal tendon, toe flexor and extensor tendon, anterior cruciate ligament, posterior cruciate ligament, knee medial and lateral collateral ligament, anterior talofibular ligament, calcaneofibular ligament, posterior talofibular ligament, anterior inferior tibiofibular ligament, posterior inferior tibiofibular ligament, ankle deltoid and spring ligament, acromioclavicular ligament, coracoclavicular ligament, sternoclavicular ligament, elbow lateral collateral ligament, elbow medial collateral ligament, radial annular ligament, ligament of the wrist, plantar plate, or collateral ligament of a finger, thumb, or toe.
19 . The method of claim 16 , wherein the composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes.
20 . The method of claim 16 , wherein the selective androgen receptor modulator comprising one or more of enobosarm or ligandrol, wherein the composition optionally further comprises an aromatase inhibitor.
21 . The method of claim 16 , wherein the composition comprises a combination of sex steroids and/or sex steroid equivalents formulated to increase levels of more than one sex steroid in the subject.
22 . The method of claim 16 , wherein the drug-eluting implant comprises a suture, suture anchor, drug-loaded textile, drug-loaded patch, or combination thereof.
23 . The method of claim 16 , wherein the drug-eluting implant is configured to provide extended release of the composition.
24 . The method of claim 16 , wherein:
the estrogen is included at a dose of 0.05 mg to 8 mg; and/or
the androgen and/or androgen equivalent is included at a dose of 2.5 mg to 200 mg.
25 . The method of claim 16 , wherein the composition omits other active compounds for improving healing of the enthesis.
26 . The method of claim 16 , wherein the composition comprises a carrier, and wherein the carrier comprises a solvent, solution, emulsion, suspension, coating, isotonic agent, dispersion media, suspension media, absorption promoting agent, absorption delaying agent, suspending agent, thickening agent, preservative, antimicrobial agent, salt, liposome, polymeric micelle, microsphere, nanoparticles, or combination thereof.
27 . The method of claim 16 , wherein the drug-eluting implant is cylindrically-shaped.
28 . The method of claim 16 , wherein the drug-eluting implant comprises a xenograft, allograft, autograft, synthetic materials, or a combination thereof.
29 . A method of improving healing of an enthesis of a subject in need thereof, the method comprising:
locally administering to the subject, at a target enthesis site, an effective amount of a composition comprising
(i) an estrogen, wherein the estrogen comprises estrone, estradiol, estriol, ester thereof, ether thereof, or combination thereof,
(ii) an androgen and/or androgen equivalent, wherein the androgen comprises testosterone, dihydrotestosterone, androstenedione, ester thereof, ether thereof, or combination thereof, and wherein the androgen equivalent comprises a selective androgen receptor modulator, or
(iii) combination thereof,
wherein the composition omits selective estrogen receptor modulators,
to thereby increase levels of at least one sex steroid at the target enthesis site.